海王生物(000078.SZ):NEP018獲得藥物臨牀試驗批准通知書
格隆匯3月10日丨海王生物(000078.SZ)公佈,公司全資子公司深圳海王醫藥科技研究院有限公司(簡稱“海王醫藥研究院”)於近日收到國家藥品監督管理局核准簽發的NEP018片的《藥物臨牀試驗批准通知書》。
NEP018片是海王醫藥研究院自主研發、具有自主知識產權的新型腫瘤靶向小分子激酶抑制劑。經綜合的臨牀前研究考察,NEP018片對設計靶點具有良好選擇抑制活性,針對胃腸道腫瘤具有良好的抑制作用。藥動學組織分佈集中於胃腸道,在胃腸道腫瘤治療仍以化療藥物為主附加生物類藥物聯合治療的現狀下,該項目的開發,可一定程度上解決臨牀胃腸腫瘤靶向小分子藥物未被滿足的臨牀需求。該項目核心專利已獲發明專利授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.